NCT06477549View on ClinicalTrials.gov

BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

PHASE2RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

June 21, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2029

Conditions
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBiphenotypic Acute LeukemiaLymphoblastic LymphomaMyeloproliferative NeoplasmMyelodysplastic Syndromes
Interventions
DRUG

Bendamustine Hydrochloride

Days -7 through -6: Bendamustine 90 mg/m2 iv x 2 days

DRUG

Ruxolitinib

Days -7 through -2: ruxolitinib 5 mg tid per os

Trial Locations (1)

197022

RECRUITING

RM Gorbacheva Research Institute, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER